Key result
S-ICD proves a feasible alternative to transvenous ICDs for ventricular tachyarrhythmias without pacing needs.
Why the study?
Since the introduction of the S-ICD, numerous innovations and clinical experience have advanced its role, prompting a review of implantation considerations, patient selection, troubleshooting, and future perspectives.
This review summarizes 15 years of advancements in S-ICD therapy, highlighting its role as an alternative to transvenous ICDs and discussing future technologies like extravascular ICDs.
No takes yet. Share an insight, caveat, or question.
Supports S-ICD consideration in patients without pacing needs; leaves open need for updated comparative trials.
Dijkshoorn et al. (2024) studied this question. The subcutaneous implantable cardioverter-defibrillator (S-ICD) has proven to be a feasible alternative for treating ventricular tachyarrhythmias without pacing needs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: